- Conditions
- Bioequivalence, AUC, Cmax, Pharmacokinetics
- Interventions
- Omeprazole
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–252
of 252
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- Nasal swab under endoscopic guidance
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Healthy
- Interventions
- Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
- Drug
- Lead sponsor
- Cerecin
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Anesthesia
- Interventions
- 400uL of Kovacaine Mist, 200uL of Kovacaine Mist, 120uL of Kovacaine Mist
- Drug
- Lead sponsor
- St. Renatus, LLC
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Knee Arthritis, Osteoarthritis
- Interventions
- Knee sleeve
- Device
- Lead sponsor
- Margaret L Gourlay, MD, MPH
- Other
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Sleep Apnea, Healthy, Vasoconstriction, Vasodilation
- Interventions
- Hypoxic exposure, modified Oxford test, Oral Bosentan 62.5 mg, Hypoxic ventilatory response test
- Other · Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Columbia, Missouri • Rochester, Missouri
- Conditions
- Anesthesia
- Interventions
- Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
- Drug
- Lead sponsor
- St. Renatus, LLC
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- Pregabalin controlled release, 330 mg, low-fat, Pregabalin controlled release, 330 mg, medium-fat, Pregabalin controlled release, 330 mg, high-fat, Pregabalin immediate release, 300 mg
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hypotension
- Interventions
- Phenylephrine
- Drug
- Lead sponsor
- West-Ward Pharmaceutical
- Industry
- Eligibility
- 12 Years to 16 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia • Miami, Florida + 7 more
- Conditions
- Retinopathy of Prematurity (ROP)
- Interventions
- 1% phenylephrine and 0.2% cyclopentolate
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Caries,Dental, Apical Periodontitis
- Interventions
- Kovanaze Nasal Spray, Articaine Injection
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Richmond, Virginia